HUMIRA (adalimumab) Coupon & Price

HUMIRA (adalimumab) Coupon & Price ( visit store )
0 0
Comments Off
Want to say something? Add Comment 

Humira (adalimumab) Coupon & Price

Humira (adalimumab) is an anti-inflammatory medicine. One way to save money on the Humira retail price regardless of income and insurance status is to use Humira coupon. Use this adalimumab coupon at this online pharmacy and receive up to 75% off the sale price.

Humira is a medicine that contains the active substance adalimumab.
It is available as a solution for injection in the vial, pre-filled syringe, or pre-filled pen, all containing 40 mg adalimumab.

What is Humira used for?

Humira is an anti-inflammatory medicine. It is used to treat the following groups of patients:
adults with moderately to severely active rheumatoid arthritis (a disease that causes joint inflammation) who have not responded adequately to other treatments and adults with severe, aggravated, active rheumatoid arthritis who have not taken methotrexate (another treating rheumatoid arthritis). Humira is used in combination with methotrexate alone if the patient can not take methotrexate;

  • Adolescents aged between 13 and 17 years with polyarticular juvenile idiopathic arthritis (a rare kidney disease that causes inflammation of several joints) that did not respond adequately to other treatments. Humira is used in combination with methotrexate alone if the patient can not take methotrexate;
  • adults with active and progressive psoriatic arthritis (a disease causing squamous red plaques on the skin and inflammation of the joints) that have not responded adequately to other treatments;
  • adults with severe active ankylosing spondylitis (a disease that causes inflammation and pain in the joints of the spine) that did not respond adequately to other treatments;
  • adults with severely active Crohn’s disease (a disease that causes inflammation of the intestines) that did not respond adequately to other treatments;
  • adults with psoriasis (a disease that causes squamous red plaques on the skin) that did not respond adequately to other treatments.

For complete information, see the Summary of Product Characteristics (also part of the EPAR).
The medicine can only be obtained with a prescription.

How is Humira used?

Treatment with Humira should be started and supervised by a physician experienced in the treatment of Humira conditions.
The recommended dose is 40 mg, given as an injection under the skin once every two weeks, and an initial dose of 80 mg is given in Crohn’s disease and psoriasis, followed by 40 mg every two weeks. In patients who require a faster response to Crohn’s disease, it may be necessary to increase the first two doses (160 mg followed by 80 mg), although this may increase the risk of side effects. During treatment with Humira, patients can be given other medicines, such as corticosteroids (other anti-inflammatory drugs). After being trained, patients can inject Humira alone, with the doctor’s consent. Patients taking Humira should receive a special alert card containing a summary of the safety information about this medicine. For more information, see the prospectus.

How does Humira work?

The active substance of Humira is adalimumab, a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognize and fix to a certain structure (called antigen) that is found in the body. Adalimumab was designed to be fixed by a chemical messenger from the body, called tumor necrosis factor (TNF). This messenger is involved in the production of inflammation and presents high values ​​in patients who suffer from the diseases for which Humira is being used. By blocking TNF, adalimumab reduces inflammation and other symptoms of these diseases.

How has Humira been studied?

Humira has been studied in five studies involving patients with moderate to severe rheumatoid arthritis. In four of these studies, Humira, given alone or as an adjunct to other anti-inflammatory drugs, including methotrexate, was compared with placebo (an inactive preparation) in over 2,000 patients. The fifth study compared Humira with methotrexate alone with Humira or methotrexate alone in 799 patients who had not taken methotrexate until then.
For polyarticular idiopathic juvenile arthritis, Humira was compared with placebo, alone or in combination with methotrexate, in a major study involving 171 patients aged between four and 17 years. All patients received Humira for 16 weeks, after which they received either Humira or placebo for a further 32 weeks.
For psoriatic arthritis, Humira was compared with placebo in two studies involving 413 patients for 12 weeks. Drugs were administered alone or in combination with another anti-inflammatory drug.
For ankylosing spondylitis, Humira and placebo given as adjuvants to existing treatment were compared in two studies involving 397 patients for 12 weeks.
For Crohn’s disease, the efficacy of the first two doses of Humira (induction) was compared with placebo in two studies involving 624 patients for four weeks. Another study looked at the long-term effects (maintenance) of Humira on 854 patients for 56 weeks.
For psoriasis, Humira was compared with placebo for 16 weeks in 1,212 patients. A second study compared Humira with methotrexate and placebo in 271 patients for 16 weeks.
In all studies, the main measure of efficacy was the change in symptoms.

What benefit has Humira shown during the studies?

Humira was more effective than placebo in all the illnesses studied.
In rheumatoid arthritis, the greatest reduction in symptoms was seen in studies that examined Humira as an adjunct to methotrexate: about two-thirds of Humira-treated patients experienced a symptom reduction of at least 20% after six months compared to a quarter of those who added placebo. Also, patients who added Humira presented after one year a reduction in joint damage and a slower decline in physical function. In patients who did not take methotrexate in the past, the combination of Humira and methotrexate was also more effective than methotrexate alone.
For polyarticular idiopathic juvenile arthritis, approximately 40% of patients receiving Humira, either alone or in combination with methotrexate, experienced an increase in arthritis compared to approximately 69% of those who received placebo. However, fewer patients receiving Humira with methotrexate developed antibodies, so the result favored the use of Humira in combination with methotrexate compared to Humira alone. The fixed dose of 40 mg, which is the only currently available Humira dose, was considered appropriate only for patients aged 13 years and over.
Humira also caused a greater improvement in symptoms than placebo in studies of psoriatic arthritis, ankylosing spondylitis, phases of induction and maintenance of treatment for Crohn’s disease and psoriasis.

What is the risk associated with Humira?

In the studies, the most common side effects with Humira (seen in more than 1 patient in 10) were respiratory infections (lung and airway infections), leucopenia (low white blood cell counts) high fat lipids, headaches, abdominal pain (nausea), nausea and vomiting, skin rash, musculoskeletal pain (muscle and bone pain) and injection site reactions (including redness). Because of the increased risk of infection, patients taking Humira should be closely monitored for infections, including tuberculosis, during and up to five months after treatment. For the full list of all side effects reported with Humira, see the Package Leaflet.
Humira should not be used in people who may be hypersensitive (allergic) to adalimumab or any of the other ingredients. Humira is forbidden in patients with tuberculosis, other severe infections or moderate to severe heart failure (heart failure to pump enough blood in the body).

Why has Humira been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Humira’s benefits are greater than its risks for the treatment of rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Crohn’s disease, ankylosing spondylitis and psoriasis. The Committee recommended that Humira be given marketing authorization.

What are the measures taken to ensure the safe use of Humira?

The company that makes Humira will provide informative packs for doctors prescribing Humira. These packs will include drug safety information.

Other information about Humira:

The European Commission granted Abbott Laboratories Ltd. a marketing authorization valid throughout the European Union for Humira on 8 September 2003. The marketing authorization was renewed on 8 September 2008.

HUMIRA (adalimumab) Coupon & Price
5 (100%) 2 votes

Comments are closed.